The total incident population of Dravet Syndrome in the seven major markets was 30,820 in 2017.

Similarly, of all the Dravet Syndrome patients in the 7MM, the United States registered around 20,912 patients while Japan had nearly 2,766 patients during the year 2017.

The market size of Dravet Syndrome in 7MM in 2017 was found to be USD 79.1 Million, which is expected to grow during the forecast period 2017-2030.

Increasing research activities and increasing disease awareness are the two important factors expected to drive the Dravet Syndrome market forward in the coming years.

The key players in the Dravet Syndrome market include Zogenix, Ovid Therapeutics, PTC Therapeutics, Biocodex, GW Pharmaceuticals and others.

For more detailed information on Dravet Syndrome Market, visit: www.delveinsight.com/report-store/dravet-syndrome-market

#epilepsy #seizures #SUDEP #severemyoclonicepilepsyofinfancy #SMEI #geneticdisorder #RareDiseases #GeneticDisease #epilepsysyndrome #neurologicalcondition #Dravetsyndrome #childhoodepilepsy